CClinicalTrials.gg
TerminatedNCT01982760Updated Aug 16, 2023Results posted

DDAVP in the Reduction of Post-operative Ecchymosis in Rhinoplasty

A Phase 2 interventional study of DDAVP in Postoperative Ecchymosis, sponsored by University Hospitals Cleveland Medical Center. Terminated at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-08-16.

Sponsored by University Hospitals Cleveland Medical Center · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This is study looking at the use of a medication, Desmopressin acetate (DDAVP), to reduce bleeding, swelling, and bruising in patients undergoing cosmetic nose surgery. DDAVP is a drug used in patients with bleeding disorders. It works by activating molecules in the blood stream called platelets that promote clotting. In the study, participants who are have cosmetic nose surgery (rhinoplasty) will be randomly assigned to receive or not receive medication. Photographs taken before and shortly after surgery will be evaluated for the amount of bruising and swelling. Patients with heart, lung, kidney, or liver problems are not eligible to participate.

02

Conditions studied

  • Postoperative Ecchymosis

Browse trials for

Keywords

  • Rhinoplasty
  • Ecchymosis
  • Edema
03

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Undergoing Rhinoplasty where nasal bone osteotomy is necessary

Exclusion criteria

Exclusion Criteria:

  • Heart Disease
  • Renal Disease with decreased GFR
  • Liver Disease
04

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    DDAVP

    Arm receiving DDAVP prior to the operation. Drug is administered intravenously at .3mcg per kg, over 30 minutes prior to the operation.

    Drug: DDAVP

  • No intervention
    No DDAVP

    Patients Will not receive DDAVP prior to Rhinoplasty

Interventions

  • DrugDDAVP

    Patients Receiving DDAVP prior to operation

    Also known as: Desmopressin

05

What researchers measure

Primary outcomes

  1. Reduction in Ecchymosis and Swelling

    Photographs taken preoperatively at 1 day and 8 days post-operatively will be analyzed for bruising

    Time frame: surgery to 8 days post-operatively

Secondary outcomes

  1. Patient Behavior Factors

    Looking at the time it takes for patients to feel comfortable wearing makeup, going out in public, and returning to work

    Time frame: Surgery to 3 weeks post-operatively

06

Results

Posted Aug 16, 2023

Participant flow

Participant flow — Overall Study
MilestoneDDAVPNo DDAVP
Started140
Completed130
Not completed10
Withdrew: Physician decision10

Outcome measures

PrimaryReduction in Ecchymosis and Swelling

Photographs taken preoperatively at 1 day and 8 days post-operatively will be analyzed for bruising

Time frame:
surgery to 8 days post-operatively

No measurements were reported for this outcome.

SecondaryPatient Behavior Factors

Looking at the time it takes for patients to feel comfortable wearing makeup, going out in public, and returning to work

Time frame:
Surgery to 3 weeks post-operatively

No measurements were reported for this outcome.

Adverse events

Collected over AE data not collected. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DDAVP———
No DDAVP———

Baseline characteristics

No patients were enrolled in the control arm as the study was terminated.

Age, Categorical
Age, Categorical(Participants)DDAVPNo DDAVPTotal
<=18 years000
Between 18 and 65 years14014
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)DDAVPNo DDAVPTotal
Female909
Male505
07

Study locations

1 site
  • Lyndhurst Surgery Center
    Lyndhurst, Ohio 44124, United States
08

Registry details

Key details

Study ID
NCT01982760
Lead sponsor
University Hospitals Cleveland Medical Center
Responsible party
Sponsor
First posted
Nov 13, 2013
Start date
Dec 2013
Primary completion
Jun 25, 2015
Completion
Jun 25, 2015
Results posted
Aug 16, 2023
Last update
Aug 16, 2023

Study contacts

Bahman Guyuron, MD
principal investigator · University Hospitals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion